Total Funding
60
92
Total FundingPost-IPO Equity raised
Growth Score
5 pts
Heat Score
27 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
49255
Dicot Pharma, focused on drug discovery and development of a modern potency drug treating erectile dysfunction better than existing drugs.
- Mats Silvander: Chief Technical OfficerPast Role: Novavax, Director of Operations
About the Company
Dicot Pharma develops LIB-01 to become a new modern potency drug for the global market. The goal is to develop a completely new generation potency drugs that surpass currently available treatments. With a longer duration of action, fewer adverse effects, and a differentiated mode of action, Dicot Pharma aims to significantly improve the treatment
of erectile dysfunctions and provide affected men and couples with a better quality of life. The company's lead candidate, LIB-01, is in clinical phase 2a. Ticker Nasdaq First North Stockholm: "DICOT"
